Through a pay-back scheme organized in collaboration with Limburg’s Kankerfonds, InnoSer has recently acquired two new imagers that will enable deeper insights into our in vitro and in vivo platforms available for preclinical oncology research. The first being the ImageXpress Micro 4, a high-content, live cell imaging solution, and the second is the Lumina III In Vivo Imaging System which allows for bioluminescent imaging (BLI) of in vivo models.
ImageXpress Micro 4 –
Lumina III In Vivo Imaging System –
Want to read more?
OECD GLP Toxicology Studies for Chemical Testing: How InnoSer Supports Your Study from Study Protocol to Report
Explore InnoSer’s GLP OECD toxicology study capabilities, from study planning and dose selection to GLP execution for chemical safety programmes.Bringing your chemical substance to the market requires a robust understanding of its potential hazards to human health and...
How do you build the right immunotoxicity assessment strategy for your nonclinical safety GLP program?
From standard toxicity studies and follow-up immune-function testing to immunogenicity assessment, test-system selection, and GLP execution, this article explores how to build an effective immunotoxicity assessment strategy for biotechnology-derived therapeutics.The...
Neurodevelopmental disorder mouse models at InnoSer — TSC, Rett & STXBP1
in this month's update, we invite you to explore recent developments in rare neurodevelopmental disorders associated with epilepsy and seizure phenotypes. We highlight emerging therapeutic approaches, discuss the importance of selecting translationally relevant...